Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Mirza Khan
Targeting Epigenetics for Treatment of BRAF Mutated Metastatic Melanoma With Decitabine in Combination With Vemurafenib: A Phase Lb Study
Oncotarget
Oncology
Related publications
Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
PLoS ONE
Multidisciplinary
A Multi-Center Phase II Study of High Dose Interleukin-2 Sequenced With Vemurafenib in Patients With BRAF-V600 Mutation Positive Metastatic Melanoma
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-Treated Patients With BRAFV600-mutated Metastatic Melanoma
Clinical Cancer Research
Cancer Research
Oncology
Biomarker Analysis of On-Treatment and at Progression Biopsies From BRIM7 - A Phase 1B Trial of Combined Vemurafenib and Cobimetinib Treatment in BRAF V600 Mutated Melanoma
Journal of Translational Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
PCN87 Cost Effectiveness Evaluation of Vemurafenib, an Orphan Drug for Braf Mutant Metastatic Melanoma
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma
Dermatology Research and Practice
Dermatology
Thrombophilic Status May Predict Prognosis in Patients With Metastatic BRAFV600-mutated Melanoma Who Are Receiving BRAF Inhibitors
Journal of the American Academy of Dermatology
Dermatology
Development of Encorafenib for BRAF-mutated Advanced Melanoma
Current Opinion in Oncology
Cancer Research
Oncology
LETTER TO THE EDITOR: Management of Vemurafenib Induced Severe Arthralgia and Pyrexia in a Patient With BRAF V600E Mutated Melanoma: First Experience With a Switch to Dabrafenib
Open Dermatology Journal
Dermatology
